Table 1.
Baseline characteristics of the study population
| Characteristics | Atorva® group (n=176) |
Lipitor® group (n=170) |
P-valuea |
|---|---|---|---|
| Male sex, n (%) | 82 (46.6) | 70 (41.2) | 0.310 |
| Age (years) | 62.8±8.8 | 63.6±8.0 | 0.352 |
| Height (cm) | 160.0±8.1 | 160.4±8.6 | 0.694 |
| Weight (kg) | 64.3±9.5 | 64.2±9.7 | 0.898 |
| Systolic blood pressure (mmHg) | 125.8±13.6 | 125.4±12.4 | 0.747 |
| Diastolic blood pressure (mmHg) | 75.3±9.5 | 75.2±8.6 | 0.924 |
| Smoking, n (%) | 22 (12.5) | 20 (11.8) | 0.836 |
| Alcohol drinking, n (%) | 46 (26.1) | 42 (24.7) | 0.714 |
| Laboratory data | |||
| Creatinine (mg/dL) | 0.88±0.21 | 0.87±0.20 | 0.451 |
| AST (IU/L) | 23.1±9.4 | 22.2±6.6 | 0.278 |
| ALT (IU/L) | 23.2±12.3 | 22.6±9.4 | 0.590 |
| Total bilirubin (mg/dL) | 0.86±0.40 | 0.85±0.55 | 0.884 |
| CPK (IU/L) | 107.4±77.2 | 95.0±43.7 | 0.066 |
| Treatment goal of LDL-C | 0.167 | ||
| <100 mg/dL, n (%) | 120 (68.2) | 110 (65.5) | |
| <130 mg/dL, n (%) | 37 (21.0) | 47 (28.0) | |
| <160 mg/dL, n (%) | 19 (10.8) | 11 (6.6) |
Note:
a
P-values in intergroup comparison using independent sample t-test.
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; CPK, creatine phosphokinase; LDL-C, low-density lipoprotein cholesterol.